M&M, Glenmark Pharma, Tata Power, Bajaj Finance shares among brokerage's top Diwali 2026 picks
NiveshIQ
NSE: GLENMARK · Healthcare
Glenmark Pharmaceuticals Ltd.
₹2,382.00▲ ₹83.30 (+3.62%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on GLENMARK. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited operates across India, North America, Europe and other international markets, manufacturing generics, specialty medicines and OTC products in dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology and anti‑infective segments. The company’s revenue mix is driven by high‑margin specialty drugs such as Telma AM Biso, a bisoprolol triple‑drug combination, and a growing portfolio of complex injectables and biologics. In FY24, Glenmark reported revenue of ₹17,737 crore and net income of ₹1,798 crore, reflecting a 13‑15% revenue CAGR target and a 23% EBITDA margin goal by FY27. Recent developments include FDA inspection clearance of its Goa facility and the launch of Telma AM Biso in India, which bolstered the company’s market share
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹11,813 Cr -9.06% | ₹13,322 Cr +12.77% | ₹16,983 Cr +27.48% |
| EBITDA Margin | 10.12% | 17.65% | 26.92% |
| Net Profit | -497.90% | ₹1,047 Cr | ₹1,362 Cr +30.07% |
| EPS | ₹-53.22 | ₹37.11 | ₹48.26 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Diwali Picks 2026 : Glenmark Pharmaceuticals Ltd for the Target Rs.2,897 by Axis Securities Ltd
Glenmark Pharmaceuticals elevates Namita Shah to Sr. VP – Global Portfolio
🔒
+ 3 more stories about Glenmark Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹4, 018 Cr, PAT ₹483 Cr, EPS ₹17.11, EBITDA margin 21.7%. Growth context: revenue QoQ +6.6%, PAT QoQ +60.2%. Street verdict: inline, revenue surprise +2.6%, PAT surprise -1.1%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new capacity addition and c...
FY26 (last completed FY): revenue ₹16, 983 Cr, PAT ₹1, 362 Cr, EBITDA margin 29.6%, EPS ₹48.26. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for GLENMARK
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track GLENMARK alongside your other holdings
Unlock full GLENMARK research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Glenmark Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Glenmark Pharmaceuticals Ltd. (GLENMARK) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Glenmark Pharmaceuticals Ltd.?
Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector with a market capitalisation of ₹6,174,271.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.